Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06623136
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT06618014
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
- Conditions
- Interventions
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Target Recruit Count
- 100
- Registration Number
- NCT06612632
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT06592326
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
- Conditions
- Interventions
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 24
- Registration Number
- NCT06592599
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Henan Provincial People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06588335
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Advanced Pancreatic Cancer
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT06577532
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Oral Topotecan With Toripalimab for Patients With Endometrial Cancer
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06548763
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 34
- Registration Number
- NCT06547203
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Toripalimab Combined With Targeted Therapy and Chemotherapy With or Without Radiotherapy as First-Line Treatment for Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 208
- Registration Number
- NCT06521866
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.